Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma
| العنوان: | Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma |
|---|---|
| المؤلفون: | Li Peilu, Tingting Wang, Shunfeng Cai, Yun Huang, Weijia Fang, Yi Zheng, Ruixue Song, Nan Qin, Xiaoxuan Tu, Peng Zhao, Hangyu Zhang, Weiqin Jiang, Di Tan |
| المصدر: | Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019) Journal for Immunotherapy of Cancer |
| بيانات النشر: | BMJ Publishing Group, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | 0301 basic medicine, Cancer Research, Carcinoma, Hepatocellular, Hepatocellular carcinoma, medicine.medical_treatment, Immunology, Clinical Decision-Making, Programmed Cell Death 1 Receptor, Short Report, Biology, Carbohydrate metabolism, Antibodies, Monoclonal, Humanized, lcsh:RC254-282, 03 medical and health sciences, 0302 clinical medicine, medicine, Immunology and Allergy, Humans, Gene, Feces, Phylogeny, Pharmacology, Gut microbiome, Anti-PD-1 immunotherapy, Bacteria, Liver Neoplasms, Immunotherapy, Sequence Analysis, DNA, medicine.disease, biology.organism_classification, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Gastrointestinal Microbiome, 030104 developmental biology, Treatment Outcome, Oncology, Metagenomics, 030220 oncology & carcinogenesis, Molecular Medicine, Akkermansia muciniphila, Metabolic Networks and Pathways, Ruminococcaceae |
| الوصف: | Background Checkpoint-blockade immunotherapy targeting programmed cell death protein 1 (PD-1) has recently shown promising efficacy in hepatocellular carcinoma (HCC). However, the factors affecting and predicting the response to anti-PD-1 immunotherapy in HCC are still unclear. Herein, we report the dynamic variation characteristics and specificities of the gut microbiome during anti-PD-1 immunotherapy in HCC using metagenomic sequencing. Results Fecal samples from patients responding to immunotherapy showed higher taxa richness and more gene counts than those of non-responders. For dynamic analysis during anti-PD-1 immunotherapy, the dissimilarity of beta diversity became prominent across patients as early as Week 6. In non-responders, Proteobacteria increased from Week 3, and became predominant at Week 12. Twenty responder-enriched species, including Akkermansia muciniphila and Ruminococcaceae spp., were further identified. The related functional genes and metabolic pathway analysis, such as carbohydrate metabolism and methanogenesis, verified the potential bioactivities of responder-enriched species. Conclusions Gut microbiome may have a critical impact on the responses of HCC patients treated with anti-PD-1 immunotherapy. The dynamic variation characteristics of the gut microbiome may provide early predictions of the outcomes of immunotherapy in HCC, which is critical for disease-monitoring and treatment decision-making. Electronic supplementary material The online version of this article (10.1186/s40425-019-0650-9) contains supplementary material, which is available to authorized users. |
| اللغة: | English |
| تدمد: | 2051-1426 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cc5c8174a6ae0668ac1a53404f171deTest http://link.springer.com/article/10.1186/s40425-019-0650-9Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....7cc5c8174a6ae0668ac1a53404f171de |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20511426 |
|---|